Alectinib

{
  "id": "MLC-T-ONC-000369",
  "term": "Alectinib",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used to treat adults with certain types of non-small cell lung cancer that are ALK positive. It used in patients whose cancer has spread to other parts of the body. It is also used to help keep cancer from coming back in patients whose cancer was removed by surgery. Alectinib is also being studied in the treatment of other types of cancer. Alectinib blocks certain proteins made by the ALK gene, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Alecensa.",
    "An orally available inhibitor of the receptor tyrosine kinase anaplastic lymphoma kinase (ALK) with antineoplastic activity. Upon administration, alectinib binds to and inhibits ALK kinase, ALK fusion proteins as well as the gatekeeper mutation ALKL1196M known as one of the mechanisms of acquired resistance to small-molecule kinase inhibitors. The inhibition leads to disruption of ALK-mediated signaling and eventually inhibits tumor cell growth in ALK-overexpressing tumor cells. ALK belongs to the insulin receptor superfamily and plays an important role in nervous system development. ALK dysregulation and gene rearrangements are associated with a series of tumors."
  ],
  "synonyms": [
    "Alecensa",
    "ALK inhibitor CH5424802",
    "ALK inhibitor RO5424802"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/alectinib/"
}